Dr Nurnberger and Colleagues Reply

To the Editor: We would like to respond to the letter by de Leon regarding our recently published article on what a psychiatrist should know about genetics.1 We appreciate Dr de Leon’s interests, as this is the type of critical thinking about genetics that we are ultimately hoping to spark among psychiatrists in training and in current practice. We would also like to stress that the main objective of our article was to provide a framework for the identification of areas of genetics that psychiatrists should know, as well as mechanisms and resources to acquire that knowledge.

We agree with Dr de Leon that pharmacologists were very important in the origins of pharmacogenetics—for example, the term was first coined by a pharmacologist, Dr Werner Kalow, in the late 1950s.2 However, specialists from many areas of expertise have contributed to the development of pharmacogenomics, including oncologists, neurologists, psychiatrists, cardiologists, and others.

We agree that it is useful for our readers to be aware of the Clinical Pharmacogenetics Implementation Consortium (CPIC). The most up-to-date information can be obtained on the CPIC website (http://cpicpgx.org/guidelines). It is worth noting that CPIC guidelines point out relationships between genetic variations and blood levels of drugs, but not between genetic variations and outcomes of treatment, at least in the realm of depression. This isn’t surprising since, except for the tricyclic antidepressants, there are no robust data correlating blood levels of medications with treatment response. As this information may change in the future, we encourage readers to obtain the most updated studies when questions arise. We would also call attention to the guidelines on genetic testing in psychiatry from the International Society of Psychiatric Genetics (https://ispog.net/genetic-testing-statement); this statement includes information on pharmacogenetics and describes the value of CPIC.

It should be noted that no pharmaceutical or pharmacogenetic testing company contributed to the content or the interpretation of data in our published article.1 Furthermore, at the time when our article was written, there were few controlled clinical trials of pharmacogenetic tests in psychiatry. Very recently, evidence from a large randomized controlled trial has added to the database in this important area.3 Results were equivocal but promising. We certainly encourage additional controlled studies in this area.

To conclude, this is a rapidly evolving field, and we expect that what psychiatrists need to know about genetics will be changing year to year, with new advances continually being published. Our aim with our recent publication is to provide readers with a framework that helps guide the acquisition of such new knowledge. Although the use of testing and DNA results will certainly improve rapidly, the basic knowledge about genetics and its usefulness that we outline in our article will not change.

John I. Nurnberger Jr, MD, PhD
jnurnber@iupui.edu
Johannah Austin, PhD
Wade H. Berrettini, MD, PhD
Aaron D. Besterman, MD
Lynn E. DeLisi, MD
Dorothy E. Grice, MD
James L. Kennedy, MD
Daniel Moreno-De-Luca, MD
James B. Potash, MD
David A. Ross, MD, PhD
Thomas G. Schulze, MD
Gwyneth Zai, MD, PhD

1Indiana University School of Medicine, Indianapolis, Indiana
2University of British Columbia, Vancouver, British Columbia, Canada
3University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
4University of California Los Angeles Semel Institute of Neuroscience and Human Behavior, Los Angeles, California
5VA Boston Healthcare System and Department of Psychiatry, Harvard Medical School, Boston, Massachusetts
6Mt Sinai School of Medicine, New York, New York
7Centre for Addiction and Mental Health and University of Toronto, Toronto, Ontario, Canada
8Warren Alpert Medical School of Brown University, Providence, Rhode Island
9Johns Hopkins University School of Medicine, Baltimore, Maryland
10Yale University School of Medicine, Hartford, Connecticut
11Institute of Psychiatric Phenomics and Genomics, University Hospital, LMU Munich, Munich, Germany

Potential conflicts of interest: Dr Nurnberger has been an investigator for Assurex and is an investigator for Janssen. Dr Kennedy has been on the scientific advisory board for Assurex (unpaid) and received honoraria from Shire and Novartis for lectures. The other authors report no potential conflict of interest.

Funding/support: Support was provided by Parthenon Management Company, the National Human Genome Institute’s Inter-Society Coordinating Committee for Practitioner Education in Genomics (www.genome.gov/27554614), and the National Neuroscience Curriculum Initiative (R25 MH10107602S1 and R25 MH086466 07S1, to Dr Ross and colleagues).

Role of the sponsor: The content of this letter was determined solely by the International Society of Psychiatric Genetics through its Residency Education Committee.

Published online: April 9, 2019.
J Clin Psychiatry 2019;80(3):19lr12741a


© Copyright 2019 Physicians Postgraduate Press, Inc.

For reprints or permissions, contact permissions@psychiatrist.com. © 2019 Copyright Physicians Postgraduate Press, Inc.

J Clin Psychiatry 80:3, May/June 2019

References

